Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023

Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023

Report Details

Myeloma medicines - now discover R&D trends, opportunities, and potential revenues
What are the commercial prospects for treating multiple myeloma? Visiongain's updated report gives you predictions, helping you stay ahead. There you see financial results, technological developments, opportunities, and commercial outlooks.

In that new analysis you discover sales forecasts to 2023 at overall world market, submarket, product, and national level for those drugs. You also assess technologies, competition, and progress for treating that cancer. There find data and potentials.
Read on to explore those products and see what their future market could be worth.

Forecasts to 2023 and other information to benefit your research and analysis

Besides revenue predictions to 2023, our report gives you recent results, growth rates, and market shares. There you discover original analysis, seeing outlooks for business and developments (R&D). You also get 64 tables, 57 charts, and two interviews.

Assessment of that medical industry, showing data you need

In that study you hear what's happening for those anti-cancer medicines, learning where needs and money lie. Now see how you and your organisation can gain.

Avoid falling behind or losing influence. Instead discover information you need to stay ahead. Our study assesses those pharmaceuticals for blood cancers (haematological malignancies), helping you save time and benefit your research, analyses, and decisions.

The following sections show, then, what you get in that new investigation.

Forecasting of the world market and segments for that cancer therapy

Discover in our report overall world drug revenue to 2023 for multiple myeloma. You also see individual revenue predictions for five therapeutic submarkets at world level:
• Immunomodulators
• Proteasome inhibitors
• Monoclonal antibodies (mAbs)
• Kinase inhibitors
• Other agents.

How will sales of those therapies expand? Which drug classes will generate most money? There you assess prospects for revenue growth, seeing where you can benefit from the treatment of multiple myeloma (plasma cell myeloma or Kahler's disease).

You also discover forecasts by agent, seeing how they can succeed.

Predictions for myeloma-treating products - find what revenues are possible

How will those cancer-treating drugs perform to 2023 at world level? Our study forecasts myeloma sales of six top brands and four expected medicines, including these:
• Revlimid
• Velcade
• Thalomid
• Zometa
• Pomalyst
• Elotuzumab.

There you find each agent's potential. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.

You also find geographical predictions.

National markets - where will highest revenues and sales growth occur?

In developed and developing countries, multiple myeloma therapies will give opportunities to pharmaceutical companies. You see where and how, from 2013, understanding potentials.

In our report you find individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries - Brazil, Russia, India, and China.

There you find countries with highest revenues and predicted sales growth. Our work explains. Discover the future of those products, hearing about progress in that healthcare field and seeing what it means.

There you assess trends in oncology and tackling those diseases.

Issues affecting developers, producers, and sellers of myeloma-treating medicines

Our study explains forces affecting that industry and market from 2013, including these:
• Therapy by induction, maintenance, and salvage methods
• Research and development (R&D) for those blood
1. Executive Summary

1.1 What This Report Covers
1.2 Multiple Myeloma: World Drug Market Overview 2013-2023
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Introduction to Multiple Myeloma and its Treatment

2.1 What is Multiple Myeloma?
2.2 What Are Plasma Cells?
2.3 What Causes Multiple Myeloma?
2.4 Signs and Symptoms of the Disease
2.5 Demographic Risk Variation in Multiple Myeloma
2.6 Stages of the Disease
2.6.1 The Durie-Salmon Staging System and the International Staging System
2.7 Treatment of Multiple Myeloma
2.7.1 Induction Therapy
2.7.2 Maintenance Therapy
2.7.3 Salvage Therapy
2.8 Present and Future Options for Treating Multiple Myeloma: Summary

3. The World Multiple Myeloma Drug Treatment Market, 2013-2023

3.1 The World Multiple Myeloma Drug Treatment Market in 2012
3.2 Multiple Myeloma Drug Treatment: Overarching Market Forecast 2013-2023
3.3 World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass: Comparison of Revenue and Market Share, 2018 and 2023
3.4 The World Multiple Myeloma Drug Treatment Market by Therapeutic Subclass: Grouped Revenue Forecasts, 2013-2023
3.5 Immunomodulators for Multiple Myeloma: Dominating the Market Throughout the Forecast Period
3.5.1 Immunomodulators: Revenue Forecast 2013-2023
3.6 Proteasome Inhibitors: A Cornerstone in Multiple Myeloma Drug Treatment
3.6.1 Proteasome Inhibitors: Revenue Forecast 2013-2023
3.7 Monoclonal Antibodies: Market Launch Anticipated in 2015
3.7.1 Monoclonal Antibodies: Revenue Forecast 2013-2023
3.8 Kinase Inhibitors: A Class of Advanced Cancer Medications
3.8.1 Kinase Inhibitors: Revenue Forecast 2013-2023
3.9 Summary: Growth of the Multiple Myeloma Drug Treatment Market, 2013-2023

4. Leading National Markets for Multiple Myeloma Drug Treatment, 2013-2023

4.1 The Leading National Markets in 2012
4.2 The Leading National Markets: Comparison of Revenue and Market Share, 2018 and 2023
4.3 The Leading National Markets for Multiple Myeloma Drug Treatment: Grouped Revenue Forecasts, 2013-2023
4.4 The US Will Continue to Dominate the Multiple Myeloma Drug Treatment Market from 2013-2023
4.5 The EU5 Countries
4.5.1 Germany: The Largest EU5 Market Will Have the Lowest Levels of Growth
4.5.2 France: Steadily Decreasing Market Share
4.5.3 Italy: High Growth Between 2013 and 2016
4.5.4 The UK: Strongest Growth of the EU5 from 2018-2023
4.5.5 Spain: The Smallest Market of the EU5
4.6 Japan: Delays in Regulatory Approval
4.7 China: Pursuing Domestic Oncology R&D
4.8 Brazil: Governmental Healthcare Investments Support Growth
4.9 Russia: Poor Treatment Outcomes Mean Demand for More-Effective Therapy is High
4.10 India: A Strong Domestic Drug Industry Limits Market Share

5. The Leading Drugs of the World Multiple Myeloma Market, 2013-2023

5.1 Immunomodulators and Proteasome Inhibitors Dominate the Market in 2012
5.2 Leading Multiple Myeloma Drugs: Comparison of Revenue and Market Share, 2018 and 2023
5.3 Leading Multiple Myeloma Drugs: Grouped Revenue Forecasts, 2013-2023
5.4 Revlimid: Market Domination Will Continue
5.4.1 Revlimid: Driving and Restraining Forces
5.4.2 Revlimid: Revenue Forecast 2013-2023
5.5 Velcade: Generic Competition Expected
5.5.1 The Driving and Restraining Factors for Velcade
5.5.2 Velcade: Revenue Forecast 2013-2023
5.6 Thalomid: A 1st Line Treatment, But Revenue is Declining
5.6.1 Driving and Restraining Factors for Thalomid
5.6.2 Thalomid: Revenue Forecast, 2013-2023
5.7 Zometa: Facing Generic Competition
5.7.1 Driving and Restraining Factors for Zometa
5.7.2 Zometa: Revenue Forecast, 2013-2023
5.8 Kyprolis: The 2nd Generation Proteasome Inhibitor Will Capture a Large Market Share
5.8.1 The Driving and Restraining Factors for Kyprolis
5.8.2 Kyprolis: Revenue Fo